Peter A. McCullough

Peter Andrew McCullough (born December 29, 1962) is an American cardiologist known for his previous roles as vice chief of internal medicine at the Baylor University Medical Center in Dallas, Texas, and professor at Texas A&M University. He also served as editor-in-chief of the journals Reviews in Cardiovascular Medicine and Cardiorenal Medicine. McCullough gained further recognition during the COVID-19 pandemic for his advocacy of early treatments, including hydroxychloroquine, and for his dissent from mainstream public health guidance.

Career[edit | edit source]

McCullough has had a distinguished career in cardiology, with significant contributions in clinical practice, research, and academia. He has previously served as vice chief of internal medicine at the Baylor University Medical Center in Dallas, Texas and as a professor at Texas A&M University.

As an editor-in-chief of two prominent medical journals, Reviews in Cardiovascular Medicine and Cardiorenal Medicine, McCullough has influenced the dissemination and interpretation of cardiovascular research.

COVID-19 Pandemic[edit | edit source]

During the COVID-19 pandemic, McCullough has been a vocal proponent of early treatments, including the use of hydroxychloroquine. His stance has caused controversy, as his recommendations often contradicted the guidance of major public health institutions, including the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), which have cautioned against the use of hydroxychloroquine outside of clinical trials due to concerns about its safety and efficacy.

McCullough has been criticized for contributing to COVID-19 misinformation. Critics argue that his endorsement of unproven treatments has the potential to harm public health efforts to control the pandemic.

Controversy and Criticism[edit | edit source]

McCullough's views on the treatment of COVID-19, especially his endorsement of hydroxychloroquine, have been met with significant criticism. The WHO, CDC, and other public health authorities have cautioned against the use of hydroxychloroquine for the treatment of COVID-19 outside of clinical trials, citing lack of evidence for its effectiveness and potential risks, including cardiac side effects.

Despite the criticism, McCullough has remained steadfast in his views and continues to advocate for early treatment strategies that diverge from mainstream guidance.